阅读说明：本技术 线粒体功能改善剂 (Mitochondrial function-improving agent ) 是由 伊藤孝 瀬藤光利 尾崎悟 沟口智奈弥 浅见幸夫 于 2019-09-26 设计创作，主要内容包括：本发明提供线粒体功能改善剂,其含有属于香肠乳杆菌(Lactobacillus farciminis)或乳酸片球菌(Pediococcus acidilactici)的乳酸菌、该乳酸菌的培养物、或该乳酸菌的培养上清液。(The present invention provides a mitochondrial function improver comprising a lactic acid bacterium belonging to Lactobacillus casei (Lactobacillus casei) or Pediococcus acidilactici (Pediococcus acidilactici), a culture of the lactic acid bacterium, or a culture supernatant of the lactic acid bacterium.)

1. A mitochondrial function-improving agent comprising: a lactic acid bacterium belonging to Lactobacillus casei (Lactobacillus casei) or Pediococcus acidilactici (Pediococcus acidilactici), a culture of the lactic acid bacterium, or a culture supernatant of the lactic acid bacterium.

2. The mitochondrial function improver according to claim 1, which is used for metabolic function improvement use, life prolonging use, anti-aging use, motor ability reduction improvement use, muscle strength reduction inhibition use, nervous system abnormality recovery use, or cognitive function improvement use.

3. A food, drink, drug or cosmetic comprising the mitochondrial function improving agent according to claim 1 or 2.

4. A lactic acid bacterium is Lactobacillus casei (Lactobacillus casei) OLL204082 strain (deposit No. NITE BP-02635) or Pediococcus acidilactici (deposit No. NITE BP-02634) OB7260 strain.

Technical Field

The present invention relates to a mitochondrial function improver.

Background

It is known that since ancient times, humans are eager for being long-lived.

As a method for prolonging the life even if the life cannot be prolonged, various methods are known. Among them, a life prolonging agent, an aging inhibitor and the like containing a microorganism such as lactic acid bacteria as an active ingredient are known.

Patent document 1 discloses: fermented products obtained by fermenting plants having many dietary experiences with lactic acid bacteria, yeast, aspergillus oryzae, and the like exhibit an effect of suppressing various aging symptoms associated with aging and increasing the survival rate, and further, the present invention discloses: in the mixture of fermentates used, a portion of the fermentates may be lactic acid fermentates.

Patent document 2 discloses an invention relating to the use of intestinal bacteria for correcting lymphoma exonic rate and inflammation-complicated genotoxicity, and also discloses: the composition and method disclosed in patent document 2 can also be used for predicting, treating and/or preventing diseases including diseases associated with genomic instability, for extending the mean life span, and for delaying the onset of cancer.

Patent document 3 discloses a life prolonging agent containing, as an active ingredient, a culture and/or a cell body obtained by culturing a lactic acid bacterium belonging to Bifidobacterium longum (Bifidobacterium longum).

Patent document 4 discloses a life prolonging agent containing, as an active ingredient, a culture and/or a cell body obtained by culturing a lactic acid bacterium belonging to Lactobacillus gasseri.

Patent document 5 discloses a life prolonging agent or an aging inhibitor, which is characterized by containing a fermentation metabolite of Lactococcus lactis subsp.

Documents of the prior art

Patent document

Patent document 1: japanese patent No. 6013670

Patent document 2: japanese patent laid-open publication No. 2016-509998

Patent document 3: japanese patent laid-open publication No. 2015-096555

Patent document 4: japanese patent No. 5765832

Patent document 5: japanese patent laid-open publication No. 2015-182954

Disclosure of Invention

Problems to be solved by the invention

The present invention addresses the problem of providing a novel food or beverage material or a novel pharmaceutical material having a life-prolonging effect.

Means for solving the problems

The present inventors have conducted intensive studies to solve the above problems and found that: the present inventors have completed the present invention by finding that a novel lactic acid bacterium and a culture of the lactic acid bacterium can improve mitochondrial function and can be a food, beverage or pharmaceutical material having a life-prolonging effect.

Namely, the present invention is as follows.

(1) A mitochondrial function-improving agent comprising a lactic acid bacterium belonging to Lactobacillus casei (Lactobacillus casei) or Pediococcus acidilactici (Pediococcus acidilactici), a culture of the lactic acid bacterium, or a culture supernatant of the lactic acid bacterium.

(2) The mitochondrial function-improving agent according to (1), which is used for metabolic function-improving use, lifespan-prolonging use, anti-aging use, motor ability reduction-improving use, muscle strength reduction-suppressing use, neural system abnormality-recovering use, or cognitive function-improving use.

(3) A food or drink, a supplement (サプリメント), a pharmaceutical or a cosmetic, which comprises the mitochondrial function improving agent of (1) or (2).

(4) A lactic acid bacterium is Lactobacillus casei (Lactobacillus casei) OLL204082 strain (deposit No. NITE BP-02635) or Pediococcus acidilactici (deposit No. NITE BP-02634) OB7260 strain.

The present invention includes the following aspects.

(5) A method for improving the function of mitochondria, comprising the steps of: a lactic acid bacterium belonging to Lactobacillus Coli (Lactobacillus casei) or Pediococcus acidilactici (Pediococcus acidilactici), a culture of the lactic acid bacterium, or a culture supernatant of the lactic acid bacterium is ingested by a subject.

(6) The method according to (5), which is aimed at improvement of metabolic function, prolongation of life, aging resistance, improvement of motor ability decrease, use of suppression of muscle strength decrease, recovery from abnormal nervous system, or improvement of cognitive function.

(7) Use of a lactic acid bacterium belonging to Lactobacillus casei (Lactobacillus casei) or Pediococcus acidilactici (Pediococcus acidilactici), a culture of the lactic acid bacterium, or a culture supernatant of the lactic acid bacterium in the manufacture of a mitochondrial function-improving agent.

(8) The use according to (7), in the manufacture of a mitochondrial function-improving agent for the purpose of improving metabolic function, prolonging life, preventing aging, improving motor performance, suppressing decrease in muscle strength, recovering from abnormal nervous system, or improving cognitive function.

(9) A lactic acid bacterium belonging to Lactobacillus casei (Lactobacillus casei) or Pediococcus acidilactici (Pediococcus acidilactici), a culture of the lactic acid bacterium, or a culture supernatant of the lactic acid bacterium, for use in the production of a mitochondrial function-improving agent.

(10) The lactic acid bacterium, the culture of the lactic acid bacterium, or the culture supernatant of the lactic acid bacterium according to (9), which is used for producing a mitochondrial function-improving agent for the purpose of improving metabolic function, prolonging life, preventing aging, improving motor performance, suppressing decrease in muscle strength, recovering from abnormal nervous system, or improving cognitive function.

(11) A lactic acid bacterium belonging to Lactobacillus casei (Lactobacillus casei) or Pediococcus acidilactici (Pediococcus acidilactici), a culture of the lactic acid bacterium, or a culture supernatant of the lactic acid bacterium, for improving the function of mitochondria.

(12) The lactic acid bacterium, the culture of the lactic acid bacterium, or the culture supernatant of the lactic acid bacterium according to (11), which is intended for improving metabolic function, prolonging life, preventing aging, improving motor performance, suppressing decrease in muscle strength, recovering from abnormal nervous system, or improving cognitive function.

(13) Use of a lactic acid bacterium belonging to Lactobacillus casei (Lactobacillus casei) or Pediococcus acidilactici (Pediococcus acidilactici), a culture of the lactic acid bacterium, or a culture supernatant of the lactic acid bacterium for improving mitochondrial function.

(14) The use according to (13), which is aimed at improvement of metabolic function, prolongation of life, aging resistance, improvement of motor ability decrease, use of suppression of muscle strength decrease, recovery from abnormal nervous system, or improvement of cognitive function.

(15) In the inventions (5) to (14), the mitochondrial function-improving agent can be used as a food, drink, supplement, drug or cosmetic.

ADVANTAGEOUS EFFECTS OF INVENTION

According to the present invention, a novel food or beverage material or a novel pharmaceutical material having a life-prolonging effect can be provided.

Drawings

Figure 1 shows the effect of administration of the culture of lactic acid bacteria in example 1 on the longevity of the animals. In the survival curve, the vertical axis represents survival rate (%), and the horizontal axis represents days after birth. In fig. 1 a to fig. 1D, MRS liquid medium administration group (cont (MRS medium)) is shown as a control, fig. 1 a shows no administration group (no treatment), fig. 1B shows an administration group of lactobacillus coli OLL204082 strain (OLL204082), fig. 1C shows an administration group of pediococcus acidilactici OB7260 strain (OB7260), and fig. 1D shows a comparative example administration group of lactobacillus reuteri MEP201805 strain (MEP 201805).

Fig. 2 shows the days after birth until knocking (clasping) occurred due to administration of the culture of lactic acid bacteria in example 1.

FIG. 3 shows the effect of the culture administered with lactic acid bacteria on the longevity of the animals in example 2. In the survival curve, the vertical axis represents survival rate (the reference is 1.00), and the horizontal axis represents postnatal day. Fig. 3 a shows the results of administration of each lactic acid strain of lactobacillus coli to the group, and fig. 3B shows the results of administration of each lactic acid strain of pediococcus acidilactici to the group.

FIG. 4 shows the days after birth until tapping occurred due to administration of the culture of lactic acid bacteria in example 2.

FIG. 5 shows the effect of the administration of cultures of P.lactis strain OB7260 on grip strength per unit body weight.

Detailed Description

Hereinafter, embodiments for carrying out the present invention will be described in detail. The present invention is not limited to the following embodiments, and various modifications can be made within the scope of the present invention.

The mitochondrial function-improving agent of the present invention contains a lactic acid bacterium belonging to Lactobacillus casei (Lactobacillus casei) or Pediococcus acidilactici (Pediococcus acidilactici), a culture of the lactic acid bacterium, or a culture supernatant of the lactic acid bacterium.

In the present specification, the mitochondrial function improver of the present invention contains a lactic acid bacterium belonging to Lactobacillus casei (Lactobacillus caseii) or Pediococcus acidilactici (hereinafter, may be collectively referred to as "lactic acid bacterium of the present invention" in the present specification), and is not particularly limited as long as it contains the lactic acid bacterium of the present invention.

That is, the lactic acid bacterium of the present invention may be contained in a suspension state, or may be isolated and contained.

Further, a culture supernatant obtained when the lactic acid bacterium of the present invention is cultured may be contained.

In the present invention, lactic acid bacteria belonging to the genus Lactobacillus casei (Lactobacillus casei) or Pediococcus acidilactici (Pediococcus acidilactici) are not particularly limited as long as they are classified into Lactobacillus casei (Lactobacillus casei) or Pediococcus acidilactici (Pediococcus acidilactici) according to the International rules for nomenclature for bacteria.

The Lactobacillus casei (Lactobacillus farcinis) is not particularly limited, and examples thereof include Lactobacillus casei (Lactobacillus farcinis) OLL204082 strain.

The Pediococcus acidilactici (Pediococcus acidilactici) is not particularly limited, and includes, for example, Pediococcus acidilactici (Pediococcus acidilactici) strain OB 7260.

Lactobacillus casei (Lactobacillus casei) OLL204082 and Pediococcus acidilactici (OB7260) are lactic acid bacteria deposited internationally under the Budapest treaty at the national institute of technical and technical evaluation on day 14 (deposit) in 2018, patent microorganism Collection (NPMD) (Chamber 2-5-8122 of Gentianjin, Qianye county, Japan) as deposit numbers NITE BP-02635 and NITE BP-02634, respectively.

In the present specification, the mitochondrial function improver of the present invention contains a culture of a lactic acid bacterium belonging to Lactobacillus casei (Lactobacillus caseii) or Pediococcus acidilactici (hereinafter, this culture may be collectively referred to as "the culture of the lactic acid bacterium of the present invention" in the present specification), and the culture containing the lactic acid bacterium of the present invention is not particularly limited.

The culture of the lactic acid bacterium of the present invention may contain the lactic acid bacterium of the present invention, or the lactic acid bacterium of the present invention may be removed by a known method such as filtration, dialysis, precipitation, centrifugation, or the like.

When the lactic acid bacterium of the present invention is contained in a culture of the lactic acid bacterium of the present invention, it may be contained as a live bacterium or a dead bacterium.

The culture of the lactic acid bacterium of the present invention may contain a medium component for culturing the lactic acid bacterium of the present invention, or may be partially removed.

The culture, which may directly contain the lactic acid bacteria of the present invention, may be concentrated and contained, may be contained in the form of a liquid, and may be contained in the form of a solid.

The culture of the lactic acid bacterium of the present invention may be a culture supernatant obtained when the lactic acid bacterium of the present invention is cultured. The mitochondrial function improving agent of the present invention may contain a culture supernatant obtained when the lactic acid bacterium of the present invention is cultured.

In the present invention, the culture of the lactic acid bacterium of the present invention can be obtained by culturing the lactic acid bacterium of the present invention.

The medium for culturing the lactic acid bacteria of the present invention is not particularly limited. The method for culturing the lactic acid bacteria of the present invention is not particularly limited.

The mitochondrial function-improving agent of the present invention can improve mitochondrial function in cells whose mitochondrial function has been reduced, thereby activating the cells, and therefore can be used for metabolic function improvement, life prolongation, anti-aging, motor ability reduction improvement, muscle strength reduction inhibition, abnormal recovery of the nervous system, cognitive function improvement, and the like.

The lactic acid bacteria of the present invention, the culture thereof, and the culture supernatant thereof can also be used for improving the function of mitochondria.

The present invention may be a method for improving the function of mitochondria in a subject by allowing the subject to ingest the lactic acid bacterium of the present invention, a culture thereof, and a culture supernatant thereof.

In the present invention, the lactic acid bacterium, the culture thereof, and the culture supernatant thereof of the present invention can be used for the purpose of improving metabolic function, prolonging life, preventing aging, improving motor ability deterioration, suppressing muscle strength deterioration, recovering abnormal nervous system, or improving cognitive function in a subject by being ingested by the subject.

The present invention may be a method for improving metabolic function, prolonging life, delaying aging, improving motor ability reduction, suppressing decrease in muscle strength, recovering from abnormal nervous system, or improving cognitive function in a subject by allowing the subject to ingest the lactic acid bacterium of the present invention, a culture thereof, and a culture supernatant thereof.

The present invention may be a method for treating or preventing a disease associated with the function of mitochondria in a subject by allowing the subject to ingest the lactic acid bacterium of the present invention, a culture thereof, and a culture supernatant thereof.

Examples of diseases related to mitochondrial function include metabolic dysfunction, decreased lifespan, aging, reduced motor ability, reduced muscle strength, neurological dysfunction, and reduced cognitive function.

The mitochondrial function-improving agent of the present invention can be used as a food or drink, a supplement, a medicament, or a cosmetic.

The food, drink, supplement, medicine or cosmetic can be used for human, and also can be used for pet and livestock.

In this specification, the term "drug" also includes the concept of quasi-drug. In the present specification, the cosmetic may be a cosmeceutical comprising the lactic acid bacterium of the present invention, a culture thereof, and a culture supernatant thereof.

In the present invention, the mitochondrial function improving agent may be used in combination with other components for metabolic function improvement, life prolongation, anti-aging, motor ability reduction improvement, muscle strength reduction inhibition, recovery from abnormal nervous system, cognitive function improvement, and the like.

As the other components, appropriate selection can be made.

When the mitochondrial function improver of the present invention is used as a cosmetic, the form thereof is not particularly limited, and may be an emulsion, a cream, an aqueous solution, a mask, or the like.

The cosmetic composition may contain various ingredients used in cosmetics, and the various ingredients are not particularly limited, and examples thereof include oily ingredients, emulsifiers, humectants, thickeners, medicinal ingredients, preservatives, pigments, powders, pH adjusters, ultraviolet absorbers, antioxidants, and fragrances, and the amount of the ingredients added is not particularly limited.

When the mitochondrial function improver of the present invention is used as a drug (including a quasi-drug), it can be administered orally or parenterally as a drug, a pharmaceutical preparation and/or a pharmaceutical composition.

For oral administration, known administration forms such as tablets, capsules, coated tablets, troches, solutions, suspensions and other liquid formulations can be used.

Examples of parenteral administration include: administration by injection intravenously, intramuscularly, or subcutaneously; transmucosal administration via nasal cavity, oral cavity, etc., using powders, drops, sprays, aerosols, or the like; rectal administration using creams or suppositories and the like; transdermal administration using a patch, liniment or gel, etc.

The route of administration is preferably oral administration or intravenous administration by injection.

When the mitochondrial function improving agent of the present invention is used as a pharmaceutical preparation and/or a pharmaceutical composition, it may suitably contain a suitable pharmaceutically acceptable carrier well known to those skilled in the art depending on the form of administration and the like.

The pharmaceutically acceptable carrier is not particularly limited, and examples thereof include antioxidants, stabilizers, preservatives, flavoring agents, coloring agents, solubilizing agents, solubilizers, surfactants, emulsifiers, antifoaming agents, viscosity modifiers, gelling agents, absorption promoters, dispersants, excipients, and pH regulators.

In the present invention, the administration amount and administration schedule of the lactic acid bacterium of the present invention, its culture, and its culture supernatant can be adjusted depending on the required amount, treatment method, disease, degree of necessity, and the like of each treatment subject.

The administration amount can be specifically determined according to age, body weight, general health state, sex, diet, administration time, administration method, excretion rate, combination of drugs, and disease state of the patient, and may be determined in consideration of other factors.

The lactic acid bacterium of the present invention, its culture, and its culture supernatant preferably contain an effective amount that can exert a desired effect.

The administration amount of the lactic acid bacterium of the present invention, its culture, and its culture supernatant for 1 day varies depending on the state and body weight of the subject, the kind of the compound, the administration route, and the like, and is usually about 0.01 to 1000 mg/person/day, preferably 0.1 to 500 mg/person/day in the case of non-oral administration, and is usually about 0.01 to 5000 mg/person/day, preferably 0.1 to 3000 mg/person/day in the case of oral administration.

When the lactic acid bacterium of the present invention, its culture, and its culture supernatant are ingested by a subject in need thereof, the subject in need thereof is not particularly limited, and is mammals (also referred to as mammals) or birds, preferably humans, but may be pets, livestock, and the like.

The subject may also suffer from diseases associated with mitochondrial function, such as mitochondrial dysfunction or mitochondrial dysfunction.

When the mitochondrial function improver of the present invention is used as a food or beverage, the form thereof is not particularly limited. For example, in the present invention, the mitochondrial function improving agent of the present invention is suitably used as a nutritional supplement or a supplement.

When the mitochondrial function improver of the present invention is used as a food or beverage, the amount of the lactic acid bacterium, its culture, and its culture supernatant of the present invention to be administered for 1 day varies depending on the state and body weight of the subject, the kind of the compound, the route of administration, and the like, and is usually about 10 to 1000 g/person/day, preferably 50 to 200 g/person/day.

The food or beverage composition may contain various components used in foods or beverages, and the various components are not particularly limited, and examples thereof include oily components, emulsifiers, humectants, thickeners, medicinal components, preservatives, pigments, powders, pH adjusters, ultraviolet absorbers, antioxidants, and perfumes, and the amount of the components added is not particularly limited.

Examples of the food and drink include fermented tea, fermented milk, yogurt, lactic acid bacteria drink, fermented sausage, cheese, soybean paste, kimchi, pickles, and salt koji.

In the present invention, the mitochondrial function improver of the present invention can be used for pet purposes, and is preferably used as pet foods and drinks such as pet cosmetics, pet drugs, pet foods, and nutritional supplements/supplements for animals such as mammals and birds. The mitochondrial function improver of the present invention can be used for livestock, and can also be used as livestock foods and beverages such as livestock cosmetics, livestock pharmaceuticals, and livestock feeds.

In the present invention, the pet and livestock are not particularly limited, and examples thereof include dogs, cats, birds, rabbits, guinea pigs, sheep, cattle, horses, and pigs, and also reptiles and amphibians.

Examples

The present invention will be described in more detail with reference to the following examples, but the present invention is not limited to the following examples. In addition, various modifications may be made without departing from the scope of the technical idea of the present invention.

Example 1

(1) Preparation of culture of lactic acid bacteria

Lactobacillus Coli OLL204082, Pediococcus acidilactici OB7260 and Lactobacillus reuteri MEP201805 were cultured in MRS liquid medium (Difco Laboratories MRS Broth model: #288130) under anaerobic conditions using Anerpack ("Anerpack/Kenki" manufactured by Mitsubishi gas chemical Co., Ltd.) for 18 hours, respectively. The culture temperature was 30 ℃ for the OLL204082 and OB7260 strains and 37 ℃ for the MEP201805 strain. 5mL of the culture solution was centrifuged at 2330g for 10 minutes, and then 4.25mL of the supernatant was removed. The pellet was suspended with the remaining supernatant as an administration to mice. In addition, as a control, MRS liquid medium was also used as an administration substance.

(2) Animal testing

Ndufs4(NADH dehydrogenase ion-sulfur protein 4, NADA dehydrogenase iron-sulfur protein 4) KO mice made according to Cell Metabolism 7,312-320(2008) were divided into the following groups. The number of n in each group is marked simultaneously.

The group was administered with a culture of lactic acid bacteria or MRS liquid medium for 4 weeks from weaning (about 3 weeks) to 50 days after birth. The administration amount was 150. mu.L/mouse/day, the administration frequency was 5 to 6 times per week, and the administration method was forced oral administration using a gastric tube.

1. No administration group (no treatment) (n ═ 11)

MRS liquid medium administration group (control) (n ═ 6)

3. Lactobacillus casei OLL204082 strain administration group (n ═ 8)

4. Pediococcus acidilactici OB7260 strain administration group (n ═ 7)

5. Lactobacillus reuteri MEP201805 strain administration group (comparative example) (n ═ 6)

(3) Evaluation item

The days after birth until death and the days after birth until knocking occurred were measured. The measurement results are shown in fig. 1 and fig. 2, respectively. Tapping is a characteristic behavior that mice take with the development of neurological abnormalities (Food funct.,4,1776-1793 (2013)).

(4) Statistical analysis

Statistical analysis utilized the online site Oasis2(https:// sbi. postech. ac. kr/Oasis2 /).

Results

The life of the Ndufs4 KO mouse was significantly prolonged compared to the MRS liquid medium administration group (control) by administering a culture of lactobacillus casei OLL204082 strain or a culture of pediococcus acidilactici OB7260 strain (fig. 1, P ═ 0.0344, 0.0844T-TEST).

In addition, the occurrence of tapping was significantly delayed compared to the MRS liquid medium-administered group (control) by administering a culture of lactobacillus casei OLL204082 strain or a culture of pediococcus acidilactici OB7260 strain (fig. 2, P ═ 0.03, 0.01T-TEST).

On the other hand, the culture given to lactobacillus reuteri MEP201805 strain did not have a significant effect on the prolongation of life span and the occurrence period of knocks (fig. 1, p-0.247T-TEST, and fig. 2, p-0.15T-TEST).

Furthermore, the Ndufs4 KO mouse is a model mouse in which mitochondria have been dysfunctional, and it is considered that these strains of lactic acid have an effect of improving mitochondrial function by administering a culture of lactobacillus casei OLL204082 strain or a culture of pediococcus acidilactici OB7260 strain to prolong the lifespan of the mouse.

Example 2

The effect on the longevity of mitochondrial disease model mice by administration of various lactic acid bacterial strains was confirmed.

(1) Preparation of culture of lactic acid bacteria

Referring to example 1, each lactic acid strain was cultured overnight at 30 ℃ in MRS liquid medium under anaerobic conditions achieved using Aneropack. 2mL of the culture solution was centrifuged at 2330g for 10 minutes, and then 1.7mL of the supernatant was removed. The pellet was suspended with the remaining supernatant as an administration to mice. In addition to the aforementioned administration products of OB7260 strain alone, the culture medium was centrifuged to remove the entire supernatant, and the supernatant was suspended in 0.3mL of Phosphate Buffered Saline (PBS) to prepare an administration product (hereinafter referred to as OB7260 strain PBS suspension).

(2) Animal testing

Referring to example 1, each group was administered with a culture of lactic acid bacteria or MRS liquid medium for 4 weeks from the time of weaning (about 3 weeks) to 65 days after birth of an Ndufs4 KO mouse. The administration amount was 300. mu.L/day, the administration frequency was 5 to 6 times per week, and the administration method was forced oral administration using a gastric tube.

1. No administration group (no treatment) (n ═ 20)

MRS liquid medium administration group (control) (n ═ 13)

3. Lactobacillus casei OLL204082 strain administration group (n ═ 12)

4. Lactobacillus coli strain P1804501 (n ═ 10)

5. Lactobacillus coli strain P1804502 (n ═ 7)

6. Pediococcus acidilactici OB7260 strain administration group (n ═ 11)

7. Pediococcus acidilactici strain P1804503 administration group (n ═ 9)

8. Pediococcus acidilactici strain P1804504 administration group (n ═ 9)

9. Pediococcus acidilactici OB7260 strain PBS suspension administration group (n ═ 8)

The L.coli P1804501, L.coli P1804502, L.lactis P1804503 and L.lactis P1804504 are lactic acid bacteria isolated from raw milk and stored in Kyowa Shuzo.

(3) Evaluation item

The days after birth until death and the days after birth until knocking occurred were measured. The measurement results are shown in fig. 3 and 4, respectively.

(4) Results

By administering a culture of each lactic acid bacterial strain or a PBS suspension of OB7260 strain, the lifespan of the Ndufs4 KO mouse was significantly prolonged compared to the MRS liquid medium administration group (control) (fig. 3).

In addition, by administering cultures of each lactic acid bacterial strain or PBS suspension, the occurrence period of tapping was significantly delayed compared to the MRS liquid medium administration group (control) (fig. 4, p <0.05 (T-TEST)).

It is considered that the lactic acid bacteria belonging to the species Lactobacillus mesentericus and Pediococcus acidilactici have the effect of improving mitochondrial function by not only increasing the lifespan of mice by administering the strain Lactobacillus mesentericus OLL204082 and Pediococcus acidilactici OB7260 but also increasing the lifespan of mice by administering the culture of other lactic acid strains of Lactobacillus mesentericus and Pediococcus acidilactici.

As described above, the life span of both the OB7260 strain culture-administered group and the OB7260 strain PBS suspension-administered group was significantly longer than that of the MRS liquid medium-administered group (control). In addition, the mean lifespan of the culture-administered group was 82.6 days and the PBS suspension was 72.6 days, and in both groups, the lifespan of the culture-administered group was significantly extended (P ═ 0.096T-TEST). From the above results, it is considered that OB7260 prolongs the life of the PBS suspension-administered group, and that the pellet (mainly containing the living organism of OB 7269) at the time of centrifugal separation of the culture has the function of improving mitochondria. Further, the culture as a mixture of the precipitate and the supernatant was significantly longer in life than the PBS suspension, and it was considered that the supernatant also had a mitochondrial improving function.

Example 3

Since it is known that mitochondrial dysfunction is associated with the age increase of skeletal muscle, the abnormality of skeletal muscle, and sarcopenia, the effect of age increase of healthy elderly mice on the reduction of muscle strength was confirmed.

(1) Preparation of culture of lactic acid bacteria

In the same manner as in example 2, Pediococcus acidilactici OB7260 strain was cultured overnight at 30 ℃ in MRS liquid medium under anaerobic conditions achieved by Aneropack. 2mL of the culture solution was centrifuged at 2330g for 10 minutes, and then 1.7mL of the supernatant was removed. The pellet was suspended with the remaining supernatant as an administration to mice.

(2) Animal testing

A culture of lactic acid bacteria (n-12) was administered to 22-24 months old healthy aged C57BL6J mice (male) for 2 months. As a control, a non-administration group was set. Grip strength was measured 16 days after the end of the administration period.

(3) Evaluation items (measurement of grip strength)

The tail of each mouse was pulled 10 times in the horizontal direction, and the grip strength at that time was measured with a rat/mouse grip strength measuring instrument (Komachi Kogyo, MK-380CM/F) to record the maximum value. The maximum grip strength was divided by the body weight to calculate the grip strength per unit body weight (kgf/body weight). The results are shown in FIG. 5.

(4) Results

The grip strength per body weight of aged mice was significantly improved (p <0.05, T-TEST) in the group to which the culture of Pediococcus acidilactici OB7260 strain was administered, compared to the group without administration (no treatment).

PCT/RO/134 Table